Identifies KCTD5 as a novel cancer biomarker associated with programmed cell death and chemotherapy drug sensitivity. Shi YX, Yan JH, Liu W, Deng J, et al. BMC Cancer 2023;23:408.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Shi YX, Yan JH, Liu W, Deng J, et al. Identifies KCTD5 as a novel cancer biomarker associated with programmed cell death and chemotherapy drug sensitivity. BMC Cancer 2023;23:408.
PMID: 37149576